Metabolites · 7 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review synthesizes 32 clinical studies evaluating GLP-1 receptor agonists in patients with T2DM and NAFLD. The authors conclude that GLP-1RAs may contribute to reduction of liver fat content, NASH resolution, and reduced fibrosis progression.
The authors conducted an extensive literature search of PubMed and ClinicalTrials.Gov for studies evaluating GLP-1RAs in T2DM patients with NAFLD, with follow-up of at least 12 weeks. A total of 32 studies were identified: eight with exenatide, sixteen with liraglutide, six with semaglutide, and two with dulaglutide, all reporting positive results for improving NAFLD. Liraglutide was the most investigated agent. Studies examined effects on liver biomarkers, steatosis and fibrosis indices, liver fat content, and histological data. Key limitations include the heterogeneity of study designs, diagnostic methods, populations, and follow-up durations across included studies, as well as the absence of data for efpeglenatide, lixisenatide, and albiglutide. The authors note that ongoing large trials using liver biopsy or MRI techniques will further shape clinical guidelines.
